RT3 Research Guide: GLP-1/GIP/Glucagon Triple Agonist

Overview

RT3 is a triple-agonist peptide that simultaneously activates GLP-1, GIP, and glucagon receptors. Unlike single-agonist compounds such as SM1 (GLP-1 only) or dual-agonists like TZ2 (GLP-1/GIP), RT3 engages all three pathways in a single molecule. This tri-agonist mechanism has generated significant interest in metabolic research, with published clinical trial data demonstrating effects not observed with earlier-generation compounds.^[1][2]

This guide covers what researchers should understand about RT3: its mechanism of action, how it differs from other GLP-receptor peptides, the published clinical data, proper handling for laboratory use, and what to look for when sourcing this compound for research.

Mechanism of Action

RT3 targets three distinct G protein-coupled receptors involved in metabolic regulation:

GLP-1 Receptor

Glucagon-like peptide-1 (GLP-1) receptor activation is the most well-studied pathway in this class of compounds. GLP-1 agonism has been extensively characterized in published literature for its role in glucose-dependent insulin secretion, gastric emptying modulation, and central appetite signaling. SM1 and liraglutide act exclusively through this receptor.^[5]

GIP Receptor

Glucose-dependent insulinotropic polypeptide (GIP) receptor activation adds a second incretin pathway. GIP agonism has been shown in preclinical models to enhance insulin sensitivity in adipose tissue and may contribute to lipid metabolism effects not seen with GLP-1 alone. TZ2 was the first commercial compound to combine GLP-1 and GIP agonism.^[6]

Glucagon Receptor

This is what distinguishes RT3 from all other compounds in its class. Glucagon receptor activation increases hepatic glucose output and stimulates energy expenditure through thermogenic pathways. In isolation, glucagon agonism would raise blood glucose — but when combined with GLP-1 and GIP agonism, the insulinotropic effects counterbalance the glycemic impact while preserving the metabolic rate increase. This tri-agonist balance is what makes RT3 mechanistically unique.^[3][4]

Published Clinical Data

RT3 has been evaluated in Phase 2 clinical trials published in peer-reviewed journals. The following data is drawn from published results and is presented for research context only.

Phase 2 Trial (Jastreboff et al., NEJM 2023)^[1]

A 48-week, randomized, double-blind, placebo-controlled trial enrolled 338 adults with obesity. The study evaluated multiple administered-amount tiers and reported the following observations at 48 weeks:

• The highest-concentration cohort demonstrated mean body weight reductions exceeding 24% from baseline — the largest reduction reported for any single anti-obesity compound in a controlled trial at the time of publication
• 100% of participants in the highest-concentration group achieved at least 5% body weight reduction
• Improvements in glycemic markers, lipid profiles, and blood pressure were observed across all tiers
• The most common adverse events were gastrointestinal in nature (nausea, diarrhea, vomiting), consistent with the GLP-1 agonist class

Phase 2 T2D Trial (Rosenstock et al., Lancet 2023)^[2]

A separate trial in participants with type 2 diabetes reported significant reductions in HbA1c alongside body weight reduction, suggesting metabolic effects across both glycemic and body composition endpoints.

Important note: All clinical data referenced above is from peer-reviewed publications. Heritage Labs provides RT3 for research use only and makes no therapeutic claims. Researchers should consult the primary literature directly for detailed study design and results.

How RT3 Compares

Understanding where RT3 fits relative to other GLP-receptor peptides helps researchers select the appropriate compound for their specific research questions.

Compound	Receptors	Classification	Key Distinction
SM1	GLP-1	Single agonist	Most extensively studied GLP-1 agonist; FDA-approved
TZ2	GLP-1 + GIP	Dual agonist	First approved dual-agonist; enhanced efficacy over GLP-1 alone
RT3	GLP-1 + GIP + Glucagon	Triple agonist	Only tri-agonist in clinical development; glucagon component adds energy expenditure pathway
Cagri	Amylin	Amylin analog	Different mechanism entirely; being studied in combination with SM1
Survodutide	GLP-1 + Glucagon	Dual agonist	GLP-1/glucagon without GIP; different balance than RT3

Heritage Labs carries SM1, TZ2, RT3, and Cagri for researchers who need to compare compounds directly.

Handling and Storage

RT3 is supplied as a lyophilized (freeze-dried) powder in sealed glass vials. Proper handling is critical to maintaining compound integrity throughout your research.

Before Reconstitution

• Storage: Keep lyophilized vials at -20°C for long-term storage or 2-8°C (standard refrigerator) for storage up to 90 days
• Light sensitivity: Store in original packaging away from direct light
• Allow to reach room temperature before opening the vial to prevent condensation on the powder

Reconstitution

RT3 dissolves readily in bacteriostatic water (BAC water). No acidic solvent is required. For a complete reconstitution protocol, see our Solvent Guide.

After Reconstitution

• Storage: Refrigerate at 2-8°C immediately after reconstitution
• Stability: Reconstituted solution is stable for up to 28 days when stored properly with BAC water^[7]
• Do not freeze reconstituted peptide solutions — freezing can damage the peptide structure
• Minimize vial entries: Each needle puncture increases contamination risk. Use a fresh sterile syringe for each draw.

For detailed storage guidance across all peptides, see our Peptide Storage & Handling Guide.

Available Sizes

Heritage Labs offers RT3 in four vial sizes to accommodate different research scales:

Product	Content	Best For
RT3 5mg	5mg lyophilized powder	Initial research, small-scale studies, pilot experiments
RT3 10mg	10mg lyophilized powder	Standard research protocols, the most popular size
RT3 30mg	30mg lyophilized powder	Extended studies, higher volume research
RT-3 60mg	60mg lyophilized powder	Bulk research programs, long-duration studies, best per-mg value

All RT3 vials are manufactured in the USA, third-party tested, and ship with a lot-specific Certificate of Analysis. View current COAs on our COA Portal.

What to Look for When Sourcing RT3

As a newer compound with high demand, RT3 quality varies significantly across suppliers. Researchers should evaluate the following before purchasing:

• Third-party testing: Every lot should have an independent Certificate of Analysis confirming identity (mass spectrometry) and purity (HPLC). If a vendor cannot provide a lot-specific COA, the product has not been verified.
• Purity threshold: Research-grade RT3 should test at ≥98% purity by HPLC. Lower purity indicates the presence of truncated sequences, salts, or synthesis byproducts that can confound experimental results.
• Lot tracking: Reputable vendors assign lot numbers and can trace any vial back to a specific manufacturing batch. This is essential for reproducibility — if your results need to be repeated, you need to know exactly what was used.
• Proper storage during shipping: Peptides degrade at elevated temperatures. Vendors should use packaging appropriate for the transit time.
• USA-based operations: Domestic vendors are subject to stricter quality control and shipping standards. Overseas-sourced peptides may have unclear chain of custody.

Current Research Landscape

RT3 is currently in Phase 3 clinical trials (as of 2024-2025) for obesity and type 2 diabetes. Eli Lilly is the sponsor of the clinical program. The research community is closely watching several areas:

• Metabolic effects beyond weight: Early data suggests improvements in hepatic steatosis (fatty liver), which could open new research directions
• Glucagon component contribution: Understanding how much of the observed effect is attributable to the glucagon pathway vs. GLP-1/GIP is an active area of investigation
• Duration of effect: Long-term maintenance and durability of metabolic changes remain open questions
• Combination potential: Researchers are exploring how tri-agonism compares to combination approaches (e.g., SM1 + Cagri)

Heritage Labs provides RT3 exclusively for in vitro and laboratory research applications. This compound is not approved for human use and no therapeutic claims are made or implied.

References

#	Citation (MLA)
1	Jastreboff, Ania M., et al. "Triple-Hormone-Receptor Agonist RT3 for Obesity — A Phase 2 Trial." New England Journal of Medicine, vol. 389, no. 6, 2023, pp. 514-526. DOI: 10.1056/NEJMoa2301972.
2	Rosenstock, Julio, et al. "RT3, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes." The Lancet, vol. 402, no. 10401, 2023, pp. 529-544. DOI: 10.1016/S0140-6736(23)01053-X.
3	Coskun, Tamer, et al. "LY3437943, a Novel Triple Glucagon, GIP, and GLP-1 Receptor Agonist for Glycemic Control and Weight Loss." Cell Metabolism, vol. 34, no. 9, 2022, pp. 1234-1247. DOI: 10.1016/j.cmet.2022.07.013.
4	Finan, Brian, et al. "A Rationally Designed Monomeric Peptide Triagonist Corrects Obesity and Diabetes in Rodents." Nature Medicine, vol. 21, no. 1, 2015, pp. 27-36. DOI: 10.1038/nm.3761.
5	Nauck, Michael A., and Daniel R. Quast. "Cardiovascular Safety and Benefits of SM1 in Patients With Type 2 Diabetes." Frontiers in Endocrinology, vol. 12, 2021, article 645566. DOI: 10.3389/fendo.2021.645566.
6	Frias, Juan Pablo, et al. "TZ2 versus SM1 Once Weekly in Patients with Type 2 Diabetes." New England Journal of Medicine, vol. 385, no. 6, 2021, pp. 503-515. DOI: 10.1056/NEJMoa2107519.
7	United States Pharmacopeia. "Bacteriostatic Water for Injection." USP-NF, USP Convention, 2023.